The FDA has approved a fixed dose combination of aspirin and clopidogrel to prevent a cardiovascular event in patients with atrial fibrillation, for whom warfarin is unsuitable.

The ACTIVE clinical trials were analyzed to determine if benefits outweigh risk for treatment with both aspirin and clopidogrel. The results showed that the combination of aspirin and clopidogrel is effective in treating advanced medullary thyroid carcinoma.

In a randomized, crossover study design, 51 growth hormone deficient children showed no significant improvement in growth with a once-daily dose of growth hormone, similar to results seen with accelerated release and daily dosing of growth hormone. However, the study did not provide definitive evidence of long-term clinical benefit.

From the information provided by the ACCORD Lipid trial, there was no difference in the risk of serious bleeding adverse events. Despite this, the FDA is notifying healthcare professionals that a positive test for antibodies to the hepatitis virus A vaccine is associated with Tysabri use.

The Louisiana Drug Information Center (DIC), which became operational in 1995, is located on the campus of the University of Louisiana at Monroe College of Pharmacy. The DIC serves as an information resource center for faculty, students, and healthcare professionals.

The DIC is dedicated to the professional community of the State of Louisiana for clinical decision making and for the advancement of drug information and pharmacy practice. They conduct research for the advancement of drug information and pharmacy practice. They also provide information on the availability of products, drug use evaluation support, and drug regulations/laws.

To conduct research for the advancement of drug information and pharmacy practice, the DIC provides online drug information services. They respond to drug information requests from healthcare professionals regarding the availability of medications. The DIC is associated with the Louisiana State Board of Pharmacy and is funded by both the State of Louisiana and private donations from the University of Louisiana at Monroe and the Louisiana Board of Pharmacy.

The DIC has a variety of online drug information services, including a drug compounding service, a drug rejection service, a drug regulations/laws service, a drug dosage and scheduling service, a drug use evaluation support service, and a drug information service. They are committed to providing up-to-date and accurate information to their clients.
The 9-Week Practice Guideline

New ACCP Guidelines

Generic Lexapro Approved

This new medication approved by the FDA helps to control hyperglycemia associated with Cushing's Syndrome.

Cystic Fibrosis Receives New Treatment Option

The FDA has approved Binosto (alendronate sodium) effervescent tablet for once-weekly treatment of osteoporosis in women at risk for or with postmenopausal osteoporosis. Other indications such as cystic fibrosis, chronic pancreatitis, or post pancreatectomy require a new usage label.

Two new pancreatic enzymes were approved that aid in digestion, Ultresa and Viokace which can be used in surgery involving gastrointestinal stromal tumors.

The FDA has approved Botox injections for patients with neurologically related incontinence.

Affymax's Erythropoiesis Stimulation Agent Erypro (epoetin beta) has been approved for use in anemic patients with chronic kidney disease.

FDA Approves Test that Will Detect Rare Brain Infection in Patients Taking Tysabri

The Infectious Diseases Society of America (IDSA) is proposing a plan to review certain antibiotics as therapeutics for use against drug-resistant bacteria.

Research Group Asks FDA to Fight Superbugs as Rare Diseases

Study Finds Antipsychotics in Pregnancy Possibly Associated with Neuromotor Deficits

FDA Changes Levemir Pregnancy Risk Category

Retinal Detachment Risk Associated with Oral Fluoroquinolone Use

FDA has notified healthcare professionals that there is a potential interaction between protease inhibitors and anti-tuberculosis medications.

FDA has removed routine monitoring of liver enzymes from the label on all statin drugs. Additionally, the label has been revised regarding decreased cognitive function and increased blood glucose.

Statin Drugs Label Change

FDA has notified healthcare professionals that there is a potential interaction between protease inhibitors and anti-tuberculosis medications.

FDA has removed routine monitoring of liver enzymes from the label on all statin drugs. Additionally, the label has been revised regarding decreased cognitive function and increased blood glucose.

Statin Drugs Label Change

FDA has increased the number of percent adults with controlled cholesterol.

The FDA has issued a Drug Safety Communication to clarify recommendations of dosing, warnings and adverse reactions associated with Celebrex.

FDA Clarifies Warning of Potential Risk of Abnormal Heart Rhythms with Celexa

Counterfeit Version of Bevacizumab Found

Drug Approvals

News Items

Drug Information Center

Travel/Health Information

Therapeutic Drug Monitoring

Product Compounding

Pregnancy and Lactation

Drug Regulations/Laws

Clinical Kinetics

Adverse Drug Events

To conduct research for the advancement of drug information and pharmacy practice.

Gregory W. Smith, PharmD, Director

Savanna Posey, PharmD Candidate

For comments and suggestions please email druginfo@ulm.edu

318.342.5501

www.fydi.org

COLEGE OF PHARMACY

University of Louisiana at Monroe

318.342.5501

FOR YOUR DRUG INFORMATION NEEDS!
Greetings from the Drug Information Center at the University of Louisiana at Monroe College of Pharmacy.

Please contact us and let us assist you with any drug information needs at our Louisiana Medicaid Pharmacy Benefits Management Program.

The Louisiana Drug Information Center (DIC), which became operational in 1995, is located on the campus of the University of Louisiana at Monroe (ULM). The operation objectives of the DIC are centered around the three core components of the drug information service: reference, education, and consultation.

The objectives are as follows:

- To teach pharmacy students, pharmacists, and other healthcare providers the skills of efficient literature retrieval, critical evaluation of the information, and accurate communication of a response.
- To provide information to the public and other healthcare professionals on the appropriate use of therapeutic agents.
- To provide literature retrieval assistance.

New Guidelines

- View Strep Throat Guidelines Updated
- Updated Adult Immunizations
- Revised Guideline for Pregnant HIV
- View Article
  - Nucynta ER Oral Tablets Approved for Treatment of Neuropathic Pain
  - First Cushing’s Disease Drug Released in the UK
  - FDA Approved Generic Singular
  - FDA Approved Drug for Treating Late Stage Prostate Cancer
  - View Article
  - Breast Cancer Drug Aids Survival

FDA MedWatch and Other Safety Alerts

- View Alert
  - Three lots of Propofol were recalled due to visible particles embedded in the glass. 
  - Ephedrine alkaloids were found in the dietary supplement which could cause serious adverse effects.
  - Codeine Use May Cause Risk of Life
- View Medwatch Voluntary Reporting Form
- View Sign Up to Receive Medwatch Alert Emails
- View Alert
  - The manufacture of Nimodipine issued a recall for one lot of Nimodipine 30mg due to crystallization.
- View Alert
  - Recall on Qualitest Hydrocodone Bitartrate and Acetaminophen Tablets 10 mg/500 mg
- View Alert
  - The FDA has advised consumers to discontinue use of Intestinomicina that contains chloramphenicol, which was linked to death.

Pharmacoeconomics

- View Article
  - A recent meta-analysis found that tamoxifen can help decrease gynecomastia.

FDA News

- View Article
  - The University of Michigan Health System updated guidelines on adult immunizations for preventative health care coordination.
- View Article
  - The revised guideline offers more treatment options for use of antiretroviral drugs in pregnant HIV.

FYDI newsletter không có nội dung mới.

Please contact us at 318.342.5501 if you have any questions or comments.